Literature DB >> 19110397

Long-term experience in autologous in vitro endothelialization of infrainguinal ePTFE grafts.

Manfred Deutsch1, Johann Meinhart, Peter Zilla, Norbert Howanietz, Michael Gorlitzer, Alexander Froeschl, Andreas Stuempflen, Deon Bezuidenhout, Martin Grabenwoeger.   

Abstract

OBJECTIVE: Based on a previous randomized study showing significantly superior patency rates for in vitro endothelialized expanded polytetrafluoroethylene (ePTFE) grafts we investigated whether it was feasible for a nontertiary institution to offer autologous in vitro endothelialization to all elective infrainguinal bypass patients who had no suitable saphenous vein available.
METHODS: Over a period of 15 years, 310 out of 318 consecutive nonacute patients (age 64.7 +/- 8.6) received 341 endothelialized ePTFE grafts (308 femoropopliteal: 153 above knee [AK] and 155 below knee [BK] and 33 femorodistal). Autologous endothelial cells were harvested from short segments (3.9 +/- 1.1 cm) of subcutaneous veins (80% cephalic, 11% basilic, 2% external jugular, and 7% saphenous) and grown to mass cultures within 18.9 +/- 4.5 days before being confluently lined onto fibrin glue-coated ePTFE grafts. The graft diameter was 6 mm (64%) or 7 mm (36%). The overall procedure-related delay for graft implantation was 27.6 + 7.8 days. Growth failure prevented 2.5% of patients from receiving an endothelialized graft. The mean observation period was 9.6 years. Primary patencies were obtained from Kaplan-Meier survivorship functions. Explants for morphological analysis were obtained from eight patients.
RESULTS: The overall primary patency rate of femoropopliteal grafts was 69% at 5 years (68% [AK] vs 71% [BK]) and 61% at 10 years (59% [AK] vs 64% [BK]). Primary patency of 7 mm vs 6 mm grafts was 78%/62% at 5 years and 71%/55% at 10 years. The difference between the two groups was statistically significant (log rank test P = .023; Breslow test P = .017). Stage I vs II/III patients showed 5-year patencies of 67% vs 73% (N.S.) and 10-year patencies of 61%% vs 53% (N.S.). The primary patency of femorodistal grafts was 52% at 5 years and 36% at 10 years. The limb salvage rate was 94% (fempop) vs 86% (femdistal) at 5 years and 89% vs 71% at 10 years. All retrieved samples showed the presence of an endothelium after 38.9 +/- 17.8 months.
CONCLUSION: Autologous in vitro endothelialization was shown to be a feasible routine procedure at a nontertiary hospital. Explants confirmed the presence of an endothelium years after implantation while the primary patency in the particularly challenging subgroup of patients without a suitable saphenous vein resembles that of vein grafts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19110397     DOI: 10.1016/j.jvs.2008.08.101

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  42 in total

Review 1.  Current usage and future directions for the bovine pericardial patch.

Authors:  Xin Li; Yuanyuan Guo; Kenneth R Ziegler; Lynn S Model; Sammy D D Eghbalieh; Robert A Brenes; Susun T Kim; Chang Shu; Alan Dardik
Journal:  Ann Vasc Surg       Date:  2011-01-28       Impact factor: 1.466

Review 2.  Endothelial outgrowth cells: function and performance in vascular grafts.

Authors:  Jeremy J Glynn; Monica T Hinds
Journal:  Tissue Eng Part B Rev       Date:  2013-10-10       Impact factor: 6.389

3.  Anti-platelet and tissue engineering approaches to biomaterial blood compatibilization: how well have these been translated into the clinic?

Authors:  Scott Alexander Irvine; Xia Yun; Subbu Venkatraman
Journal:  Drug Deliv Transl Res       Date:  2012-10       Impact factor: 4.617

4.  Electrospun silk fibroin-gelatin composite tubular matrices as scaffolds for small diameter blood vessel regeneration.

Authors:  Chiara Marcolin; Lorenza Draghi; MariaCristina Tanzi; Silvia Faré
Journal:  J Mater Sci Mater Med       Date:  2017-04-10       Impact factor: 3.896

5.  Physiologically Modeled Pulse Dynamics to Improve Function in In Vitro-Endothelialized Small-Diameter Vascular Grafts.

Authors:  Joseph S Uzarski; Jhon Cores; Peter S McFetridge
Journal:  Tissue Eng Part C Methods       Date:  2015-06-24       Impact factor: 3.056

Review 6.  Historical Perspective and Future Direction of Blood Vessel Developments.

Authors:  Sashka Dimitrievska; Laura E Niklason
Journal:  Cold Spring Harb Perspect Med       Date:  2018-02-01       Impact factor: 6.915

7.  Promoting Endothelial Cell Affinity and Antithrombogenicity of Polytetrafluoroethylene (PTFE) by Mussel-Inspired Modification and RGD/Heparin Grafting.

Authors:  Hao-Yang Mi; Xin Jing; James A Thomsom; Lih-Sheng Turng
Journal:  J Mater Chem B       Date:  2018-05-09       Impact factor: 6.331

8.  The blood and vascular cell compatibility of heparin-modified ePTFE vascular grafts.

Authors:  Ryan A Hoshi; Robert Van Lith; Michele C Jen; Josephine B Allen; Karen A Lapidos; Guillermo Ameer
Journal:  Biomaterials       Date:  2012-10-12       Impact factor: 12.479

9.  Antioxidant therapy reverses impaired graft healing in hypercholesterolemic rabbits.

Authors:  Michael A Rosenbaum; Keiko Miyazaki; Scott M Colles; Linda M Graham
Journal:  J Vasc Surg       Date:  2009-11-24       Impact factor: 4.268

10.  Endothelial outgrowth cells regulate coagulation, platelet accumulation, and respond to tumor necrosis factor similar to carotid endothelial cells.

Authors:  Jeremy J Glynn; Monica T Hinds
Journal:  Tissue Eng Part A       Date:  2014-07-31       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.